Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix

Rahman, Cheryl V. and Smith, Stuart J. and Morgan, Paul S. and Langmack, Keith A. and Clarke, Phil A. and Ritchie, Alison A. and Macarthur, Donald C. and Rose, Felicity R. and Shakesheff, Kevin M. and Grundy, Richard G. and Rahman, Ruman (2013) Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix. PloS one, 8 (10). e77435/1-e77435/12. ISSN 1932-6203

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under Licence Creative Commons Attribution.
Download (1MB) | Preview

Abstract

INTRODUCTION

Polymer-based delivery systems offer innovative intra-cavity administration of drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma beyond the resected cavity. Here we evaluate clinical utility, toxicity and sustained drug release capability of a novel formulation of poly(lactic-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) microparticles.

METHODS

PLGA/PEG microparticle-based matrices were molded around an ex vivo brain pseudo-resection cavity and analyzed using magnetic resonance imaging and computerized tomography. In vitro toxicity of the polymer was assessed using tumor and endothelial cells and drug release from trichostatin A-, etoposide- and methotrexate-loaded matrices was determined. To verify activity of released agents, tumor cells were seeded onto drug-loaded matrices and viability assessed.

RESULTS

PLGA/PEG matrices can be molded around a pseudo-resection cavity wall with no polymer-related artifact on clinical scans. The polymer withstands fractionated radiotherapy, with no disruption of microparticle structure. No toxicity was evident when tumor or endothelial cells were grown on control matrices in vitro. Trichostatin A, etoposide and methotrexate were released from the matrices over a 3-4 week period in vitro and etoposide released over 3 days in vivo, with released agents retaining cytotoxic capabilities. PLGA/PEG microparticle-based matrices molded around a resection cavity wall are distinguishable in clinical scanning modalities. Matrices are non-toxic in vitro suggesting good biocompatibility in vivo. Active trichostatin A, etoposide and methotrexate can be incorporated and released gradually from matrices, with radiotherapy unlikely to interfere with release.

CONCLUSION

The PLGA/PEG delivery system offers an innovative intra-cavity approach to administer chemotherapeutics for improved local control of malignant brain tumors.

Item Type: Article
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine > Division of Child Health, Obstetrics and Gynaecology
University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine
University of Nottingham UK Campus > Faculty of Science > School of Pharmacy
Identification Number: https://doi.org/10.1371/journal.pone.0077435
Depositing User: Smith, Stuart
Date Deposited: 18 Oct 2016 13:24
Last Modified: 18 Oct 2016 13:32
URI: http://eprints.nottingham.ac.uk/id/eprint/37644

Actions (Archive Staff Only)

Edit View Edit View